119 related articles for article (PubMed ID: 1497693)
1. Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus.
Uchikawa T; Murakami T; Furukawa H
Arzneimittelforschung; 1992 Mar; 42(3):322-4. PubMed ID: 1497693
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
Lee TM; Su SF; Tsai CH; Lee YT; Wang SS
Clin Sci (Lond); 2001 Sep; 101(3):305-11. PubMed ID: 11524048
[TBL] [Abstract][Full Text] [Related]
3. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Angiolillo DJ; Capranzano P; Goto S; Aslam M; Desai B; Charlton RK; Suzuki Y; Box LC; Shoemaker SB; Zenni MM; Guzman LA; Bass TA
Eur Heart J; 2008 Sep; 29(18):2202-11. PubMed ID: 18567918
[TBL] [Abstract][Full Text] [Related]
4. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion.
Ohashi S; Iwatani M; Hyakuna Y; Morioka Y
Arzneimittelforschung; 1985; 35(7A):1203-8. PubMed ID: 4074436
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Hiatt WR; Money SR; Brass EP
J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
[TBL] [Abstract][Full Text] [Related]
6. Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease.
Rao AK; Vaidyula VR; Bagga S; Jalagadugula G; Gaughan J; Wilhite DB; Comerota AJ
Thromb Haemost; 2006 Dec; 96(6):738-43. PubMed ID: 17139367
[TBL] [Abstract][Full Text] [Related]
7. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
O'Donnell ME; Badger SA; Sharif MA; Young IS; Lee B; Soong CV
J Vasc Surg; 2009 May; 49(5):1226-34. PubMed ID: 19217745
[TBL] [Abstract][Full Text] [Related]
8. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy.
Angiolillo DJ; Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Sumner S; Desai B; Charlton RK; Box LC; Zenni M; Guzman LA; Bass TA
Thromb Haemost; 2011 Aug; 106(2):253-62. PubMed ID: 21614414
[TBL] [Abstract][Full Text] [Related]
9. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding.
Goto S
Atheroscler Suppl; 2005 Dec; 6(4):3-11. PubMed ID: 16275169
[TBL] [Abstract][Full Text] [Related]
10. Cilostazol reduces restenosis after carotid artery stenting.
Takigawa T; Matsumaru Y; Hayakawa M; Nemoto S; Matsumura A
J Vasc Surg; 2010 Jan; 51(1):51-6. PubMed ID: 19879096
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
Rhee SY; Kim YS; Chon S; Oh S; Woo JT; Kim SW; Kim JW
Diabetes Res Clin Pract; 2011 Jan; 91(1):e11-4. PubMed ID: 20934769
[TBL] [Abstract][Full Text] [Related]
12. Cilostazol and peripheral arterial disease.
Pearce L; Ghosh J; Counsell A; Serracino-Inglott F
Expert Opin Pharmacother; 2008 Oct; 9(15):2683-90. PubMed ID: 18803454
[TBL] [Abstract][Full Text] [Related]
13. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole.
Nomura S; Inami N; Iwasaka T; Liu Y
Platelets; 2004 May; 15(3):167-72. PubMed ID: 15203718
[TBL] [Abstract][Full Text] [Related]
14. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease.
O'Donnell ME; Badger SA; Sharif MA; Makar RR; Young IS; Lee B; Soong CV
Angiology; 2008 Dec-2009 Jan; 59(6):695-704. PubMed ID: 18796444
[TBL] [Abstract][Full Text] [Related]
15. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease.
O'Donnell ME; Badger SA; Sharif MA; Makar RR; Young IS; Lee B; Soong CV
Vasc Endovascular Surg; 2009; 43(2):132-43. PubMed ID: 19131370
[TBL] [Abstract][Full Text] [Related]
16. The vascular effects of cilostazol.
Weintraub WS
Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):56B-60B. PubMed ID: 16498513
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic neuropathy.
Okuda Y; Mizutani M; Ikegami T; Ueno E; Yamashita K
Arzneimittelforschung; 1992 Apr; 42(4):540-2. PubMed ID: 1642679
[TBL] [Abstract][Full Text] [Related]
18. Effect of cilostazol in treating diabetes-associated microvascular complications.
Asal NJ; Wojciak KA
Endocrine; 2017 May; 56(2):240-244. PubMed ID: 28293857
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans.
Yasuda K; Sakuma M; Tanabe T
Arzneimittelforschung; 1985; 35(7A):1198-200. PubMed ID: 4074434
[TBL] [Abstract][Full Text] [Related]
20. Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation.
Cleanthis M; Bhattacharya V; Smout J; Ashour H; Stansby G
Eur J Vasc Endovasc Surg; 2009 May; 37(5):604-10. PubMed ID: 19297212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
